Suppr超能文献

具有ALK重排的肺腺癌是否存在相关的影像学特征?

Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?

作者信息

Halpenny Darragh F, Riely Gregory J, Hayes Sara, Yu Helena, Zheng Junting, Moskowitz Chaya S, Ginsberg Michelle S

机构信息

Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, United States.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United States.

出版信息

Lung Cancer. 2014 Nov;86(2):190-4. doi: 10.1016/j.lungcan.2014.09.007. Epub 2014 Sep 17.

Abstract

INTRODUCTION

5% of lung adenocarcinomas harbor rearrangements of the anaplastic lymphoma kinase (ALK) gene. This study compared computed tomography (CT) imaging features in patients with ALK rearrangements and those with EGFR mutations.

MATERIAL/METHODS: 30 patients with ALK rearrangements were studied. 97 patients with epidermal growth factor receptor (EGFR) mutations were used as controls. Features assessed included size and location of thoracic lymphadenopathy, and the size, contour, consistency and location of the primary tumor.

RESULTS

127 lung adenocarcinomas were examined. 30 (24%) tumors harbored ALK rearrangements, 97 (76%) tumors harbored EGFR mutations. ALK tumors had larger thoracic lymphadenopathy than the control group (p=0.005). Both readers identified 17 (57%) patients in the ALK group with lymph nodes >1.5cm. Reader 1 identified 19 (20%) patients in the EGFR group with lymph nodes >1.5cm, and reader 2 identified 18 (19%) (kappa 0.969). Patients with ALK rearrangements were more likely to have multifocal lymphadenopathy. Reader 1 identified 22 (73%) ALK patients versus 35 (36%) EGFR patients with multifocal thoracic nodal enlargement, while reader 2 identified 20 (67%) ALK patients versus 30 (31%) EGFR patients (kappa 0.953). 92% of ALK positive lesions were solid.

CONCLUSION

ALK positive lung adenocarcinomas are more likely than EGFR mutant lung adenocarcinomas to be associated with larger volume, multifocal thoracic lymphadenopathy. While routine testing for ALK should be standard, the presence of such characteristics in a solid tumor should further prompt testing for ALK rearrangement.

摘要

引言

5%的肺腺癌存在间变性淋巴瘤激酶(ALK)基因重排。本研究比较了ALK基因重排患者与表皮生长因子受体(EGFR)突变患者的计算机断层扫描(CT)影像特征。

材料/方法:对30例ALK基因重排患者进行研究。将97例表皮生长因子受体(EGFR)突变患者作为对照。评估的特征包括胸部淋巴结肿大的大小和位置,以及原发肿瘤的大小、轮廓、质地和位置。

结果

共检查了127例肺腺癌。30例(24%)肿瘤存在ALK基因重排,97例(76%)肿瘤存在EGFR突变。ALK基因重排的肿瘤胸部淋巴结肿大比对照组更大(p=0.005)。两位阅片者均识别出ALK组中有17例(57%)患者的淋巴结>1.5cm。阅片者1识别出EGFR组中有19例(20%)患者的淋巴结>1.5cm,阅片者2识别出18例(19%)(kappa值为0.969)。ALK基因重排的患者更易出现多灶性淋巴结肿大。阅片者1识别出22例(73%)ALK基因重排患者与35例(36%)EGFR突变患者有多灶性胸部淋巴结肿大,阅片者2识别出20例(67%)ALK基因重排患者与30例(31%)EGFR突变患者(kappa值为0.953)。92%的ALK阳性病变为实性。

结论

与EGFR突变的肺腺癌相比,ALK阳性的肺腺癌更易出现更大体积的多灶性胸部淋巴结肿大。虽然ALK的常规检测应成为标准,但实性肿瘤中出现此类特征应进一步促使进行ALK基因重排检测。

相似文献

引用本文的文献

3
Unusual presentation of rearranged metastatic non-small cell lung cancer.重排转移性非小细胞肺癌的不寻常表现。
Respir Med Case Rep. 2024 Aug 18;51:102091. doi: 10.1016/j.rmcr.2024.102091. eCollection 2024.
6
Radiomics in immuno-oncology.免疫肿瘤学中的放射组学。
Immunooncol Technol. 2021 Apr 16;9:100028. doi: 10.1016/j.iotech.2021.100028. eCollection 2021 Mar.
10
Molecular biomarkers in early stage lung cancer.早期肺癌中的分子生物标志物
Transl Lung Cancer Res. 2021 Feb;10(2):1165-1185. doi: 10.21037/tlcr-20-750.

本文引用的文献

1
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验